Heroin Addiction and Related Clinical Problems 2008; 10(2):5-10

Evaluation of  therapeutic alternatives to imprisonment for drug-dependent offenders. Findings of a comparative european multi-country study

Uchtenhagen A., Stevens A., Berto D., Frick U., Hunt N., Kerschl V., Mcsweeney T., Puppo I., Santamaria A., Schaaf S., Steffan E., Gegenhuber B., Turnbull P., Werdenich W.

Correspondence: Prof. Ambros Uchtenhagen, MD, PhD - Kirchgasse 30 - CH-8001 Zurich, Switzerland. Tel. +41-44-252 71 02, E-mail: uchtenhagen@isgf.uzh.ch

Summary: A multi-country, multi-site comparative research study has documented the feasibility of recruiting drug-dependent individuals receiving treatment as an alternative to imprisonment (‘quasi-compulsory’ treatment, in the setting of an experimental group), while comparing them with those receiving treatment in the same therapeutic institutions, on a voluntary basis (control group). The study combined qualitative and quantitative methods in describing the evolution and outcome of each case after 6, 12 and 18 months in treatment. 845 probands were recruited from 9 sites in 5 countries (Austria, Germany, Italy, UK, Switzerland), 429 in the experimental and 416 in the comparison group. Data were collected using a standardized instrument set and following a joint protocol that allowed for the testing of a number of pre-established hypotheses. Significant reductions in drug use and delinquent behaviour, together with improvements in social integration and health, were found in both groups. Higher rates of perceived external pressure to stay in treatment in the experimental group did not affect motivation of these patients as regards improvement and retention in the study. It can be concluded that the availability of treatment alternatives to imprisonment for drug dependence are a valuable policy option, under various different conditions, but that this option is open to further improvement.

Publication Type: Regular Article



Heroin Addiction and Related Clinical Problems 2008; 10(2):11-20

Motivational interventions for Methadone-Treated patients

Kantchelov A.

Correspondence: Alexander Kantchelov, MD, The Kantchelov Clinic, 102 - B, D.Hadjikocev Str., Office N.6, 1421 Sofia Bulgaria, EU- E-mail: al.kantchelov@gmail.com

Summary: Implementing a motivational approach in MMT acts as a powerful resource in influencing in a positive way the dominant programme atmosphere, staff-client interactions, quality of services and programme functioning as a whole. There are various ways in which motivational interventions can be successfully applied in MMT. The evidence to date is very encouraging in suggesting that even brief interventions can enhance client motivation and trigger significant improvement and change. The use of these promising methods in the future will depend on the creativity of clinicians and researchers in adopting, adapting and evaluating motivational interventions to make them more widely and effectively implemented in MMT clinical practice for the good of our clients.

Publication Type: Review



Heroin Addiction and Related Clinical Problems 2008; 10(2):21-26

Health care utilization and morbidity associated with Methadone and Buprenorphine Treatment

Bell J., Butler B.

Correspondence: Dr. James Bell, The Langton Centre, 591 South Dowling St., Surry Hills NSW 2010, Australia - E-mail: James.bell@sesiahs.health.nsw.gov.au

Summary: Background: Methadone and buprenorphine treatment reduce the high mortality associated with heroin addiction, but even in-treatment, Standardised Mortality Rates are high. Aim: This study investigates the nature of morbidity associated with methadone and buprenorphine treatment, and investigates predictors of health care utilization among people in a variety of treatment settings. Methods: Collation of data from earlier studies, and from published reports. Findings: In a recent study of an entry cohort, the SMR was 5.52 [4.62, 5.65]; suicide and overdose accounted for 2/3 of the mortality, but allowing for this, mortality rates remain elevated. Cancer, heart disease and respiratory disease were the three major contributors to mortality. Taken in conjunction with a recent study of medical co-morbidity, this suggests that alcohol, tobacco and other drug use represent the major factors contributing to serious illness in treated opioid addicts. In addition, side-effects of treatment may themselves contribute to some morbidity. Lack of access to health care does not appear to be a contributing factor, as opioid users consult doctors (other than their methadone doctors) at rates far higher than the general population. Predictors of doctor attendance “outside” doctors were psychological distress, and benzodiazepine use. Adjusting for these factors, we found evidence that quality of methadone treatment was a significant predictor of doctor attendance, with better clinical care being associated with less outside doctor attendance. Conclusion: There is a paradox; heroin users have significant physical illness, but their attendance for health care tends to be driven by psychological distress, and can be improved by good care within treatment programs. The priority in addressing health problems of stabilised heroin users is dealing with alcohol and tobacco problems.

Publication Type: Review



Heroin Addiction and Related Clinical Problems 2008; 10(2):27-38

GPs’ office based Metadone Maintenance Treatment in Trieste, Italy.Therapeutic efficacy and predictors of clinical response

Michelazzi A., Vecchiet F., Leprini R., Popovic D., Deltito J., Maremmani I.

Correspondence: Icro Maremmani, MD, “Vincent P. Dole” Dual Diagnosis Unit. “Santa Chiara” University Hospital, Department of Psychiatry, University of Pisa, Via Roma, 67 56100 PISA. Phone: +39 0584 790073; Fax: +39 0584 72081; E-Mail: maremman@med.unipi.it

Summary: Objective: To evaluate the effectiveness of methadone treatment carried out by General Practitioners (GPs) and to identify response treatment factors. Methods: 33 subjects with heroin addiction according to the DSM-IV-R criteria , 25 males and 8 females with an average age of 26 ± 6 years, were placed in an observational protocol with average duration of 429 ± 273 days. Retention rate, substance use, overall clinical improvement, social adaptation, quality of life and psychopathologic symptoms were used as outcome measures. In order to assess predictors of treatment response dropout and non-dropout subjects were compared at baseline. Results: At the end of the observational period, 6 patients (18.2%) had a positive outcome, 8 (24.2%) negative outcome, while 19 (57.6%) were still in treatment with a cumulative retention of 60% at the end of the third year of observation. In 25 non-dropout patients baseline-endpoint improvement results were statistically significant for substance use, global clinical evaluation, psychological, social and occupational functioning, and craving. They also showed improvement in all of investigated psychopathological and quality of life dimensions. There were no significant side effects associated with their treatment. Patients with higher severity of illness, with problematic relationships with spouse/partner, difficulty with socialization and organization of leisure, with an altered mental state at beginning of treatment, subjects with dual diagnosis (especially bipolar disorder), with greater severity of obsessive-compulsive symptoms, interpersonal sensitivity, depression, violence, with greater severity of psychopathological symptoms, with the largest number of problematic areas as regarding the quality of life, patients with a low dose of methadone given for treatment were considered most at risk for abandoning treatment. Conclusions: Methadone treatment carried out by General Practitioners appears safe and effective, especially in less severe patients treated with adequate doses, without severe psychopathology, without dual diagnoses (particularly bipolar disorder) and with quality of life impairment only in limited areas.

Publication Type: Regular article



Heroin Addiction and Related Clinical Problems 2008; 10(2):39-40

Use of Sertraline in depressed methadone maintenance patients

Trajanovska A. S., Popovska O. S.

Summary: Not Available

Publication Type: Letter to the Editor